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ABSTKACT 
Immunosuppression therapy with cyclosporine is of- 
ten hampered by significant interindividual variability 
in the metabolic clearance of the drug. It has been sug- 
gested that much of the variability in cyclosporine clear- 
ance is due to differences in the cytochrome P450 3A4 
(CYP3A4) content in the liver and intestinal mucosa. A 
study was conducted in liver transplant recipients to 
characterize hepatic CYPdA4 variability during the first 
10 days after surgery. The formation of 1’-hydroxymida- 
zolam (l‘-OH MDZ) was followed in the plasma after i.v. 
midazolam (MDZ) administration to 21 multiple-organ 
donors and to recipients of 10 of the 21 donor livers. 
Liver biopsy tissue was obtained from donors and recipi- 
ents after the in uiuo pharmacokinetic test. For liver do- 
nors, the plasma 1’-OH MDZ/MDZ concentration ratio 30 
min after the i.v. MDZ dose was well correlated with the 
hepatic CYP3A4 content (r = 0.87, P < .001). Much of the 
variability in the two parameters was attributed to the 
administration of enzyme-inducing drugs before organ 
procurement. The mean hepatic CYP3A4 content and 
plasma 1’-OH MDZ/MDZ concentration ratio in six in- 
ducer-treated donors was 4.7-fold and 2.3-fold higher 
than the respective mean value for all other donors. The 
hepatic CYP3A4 content and plasma 1’-OH M D m Z  
ratio for liver recipients, studied on postoperative day 
10, was negatively correlated with the respective param- 
eter measured in donors on day 0 (r = -0.60 for CYP3A4 
and r = -0.79 for 1’-OH MDz/MDZ; P < .05 and P < 
.01). The dynamic changes in hepatic CYP3A4 expression 
during the perioperative period, some of which appear 
to be due to the effect of enzyme-inducing drugs, help 
explain the difficulties often encountered in the achieve- 
ment and maintenance of therapeutic cyclosporine 
blood levels after liver transplantation. 
COMMENTS 
The vast majority of cyclosporine metabolism that 
occurs in human liver is catalyzed by a single drug- 
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metabolizing enzyme (a cytochrome P4501, termed 
CYP3A4. This discovery has appeared to explain most 
clinically significant drug interactions involving 
cyclosporine. For example, cyclosporine dosing require- 
ments generally increase when transplant recipients 
are treated with antiseizure drugs or the antibiotic ri- 
fampin, treatments known to increase (induce) hepatic 
CYP3A4 catalytic activity.’ Conversely, cyclosporine- 
treated patients who begin treatment with known 
CYP3A4 inhibitors, such as ketoconazole and erythro- 
mycin,‘ generally have significant reductions in their 
cyclosporine requirement. This has led to the increas- 
ingly accepted hypothesis that  catalytic activity of he- 
patic CYP3A4 is rate-limiting in the metabolism and 
elimination of cyclosporine. 
It is also appreciated that there are significant in- 
terpatient differences in the liver content and catalytic 
activity of CYP3A4, which can exist in the absence of 
treatment with known inducers or inhibitors of 
CYP3A4.2 This variation, which can exceed 30-fold in 
certain patient populations, probably reflects complex 
genetic factors, but may also reflect nongenetic factors 
such as dietary differences and concomitant diseases. 
In a simultaneously published companion manuscript,3 
Thummel e t  a1 determined clearance of intravenously 
administered cyclosporine and, on the same day, per- 
formed liver biopsies in 10 liver transplant recipients. 
The liver biopsy content of CYP3A4, which varied more 
than 20-fold in these patients, correlated well with the 
intravenous cyclosporine clearance measurements ( r  
= .81; P < .01). This provided the most direct evidence 
to date that differences in liver CYP3A4 activity are 
substantial and largely determine differences in sys- 
temic clearance of cyclosporine observed among liver 
transplant recipients. 
In the current studies, the investigators directly ad- 
dress two hypotheses. First, the investigators propose 
that the intravenous sedative midazolam, a known 
CYP3A4 substrate, can be used to estimate liver cata- 
lytic activity of CYP3A4 in patients, obviating the need 
for liver biopsy. In support of this hypothesis, the inves- 
tigators found in 10 liver recipients an impressive cor- 
relation between the liver biopsy specimen content of 
CYP3A4 and the systemic clearance of midazolam.’ In 
19 liver donors they also found a good correlation be- 
tween the liver content of CYP3A4 and the ratio of 1’- 
OH midazolam (the major midazolam metabolite pro- 
duced by CYP3A4) and parent midazolam determined 
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in a single blood collection obtained 30 minutes after 
the intravenous dose. This suggests that a full kinetic 
study may not be necessary and that an estimate of 
liver CYP3A4 activity using midazolam may require 
only 30 minutes at the bedside. 
The second hypothesis tested in these studies was 
that there are changes in the CYP3A4 activity when 
the liver is removed from the donor and placed in the 
recipient. To address this, the investigators obtained 
biopsy specimens from 10 donor livers and repeated 
the biopsies in the same livers 10 days after trans- 
plantation. The 30-minute midazolam test was also ad- 
ministered at the time of each liver biopsy, and the 
results closely mirrored the CYP3A4 concentrations ob- 
tained directly in the liver biopsy specimens. Donors 
that had been receiving the known CYP3A4 inducers, 
phenytoin or phenobarbital,’ generally had the highest 
liver levels of CYP3A4. Livers obtained from these do- 
nors showed a profound decrease in CYP3A4 activity 
after transplantation, presumably because the recipi- 
ents were not receiving antiseizure drugs. In contrast, 
livers obtained from donors who were not receiving 
known inducers generally had increases in CYP3A4 
content 10 days after the livers were placed in the recip- 
ients. The investigators suggest that steroid medica- 
tions given to the recipients, but generally not received 
by the donors, may account for this apparent induction. 
This is plausible because some steroid medications 
have been shown to induce CYP3A4 in human hepato- 
cytes.’ The inverse correlation between pretrans- 
plantation and posttransplantation values for liver 
CYP3A4 content found by the investigators (see ab- 
stract), therefore, appears to have been predictable 
based on differences in the medications received by the 
donors and recipients. The investigators reasonably 
speculate that such wide swings in liver CYP3A4 activ- 
ity may largely account for the difficulty in achieving 
stable cyclosporine blood levels during the early postop- 
erative period. It logically follows that knowledge of the 
activity of CYP3A4 might be useful to transplantation 
physicians attempting to  individualize dosing of the 
drug. 
Should we start using midazolam to measure 
CYP3A4 activity in our transplant recipients? Clearly 
more research needs to  be performed because the num- 
ber of patients studied is quite small and clinical utility 
was not investigated. However, the use of midazolam 
as a probe in this way is attractive because the pro- 
longed elimination kinetics of cyclosporine makes dos- 
ing based on blood levels alone largely empiric during 
the first few days after surgery. Moreover, the rapid 
changes in CYP3A4 that Thummel et a1 observed dur- 
ing the postoperative period might make it desirable 
to  have frequent (i.e., daily) measurements of CYP3A4 
activity. In addition, CYP3A4 has been shown to be the 
major liver enzyme that catalyzes metabolism of many 
other medications, including FK506 and rapamycin.2 
Therefore, the data obtained from this test might give 
useful information concerning dosing of multiple drugs. 
Some issues dampen enthusiasm for the midazolam 
test, however. Probably the major issue is that the 
assay used by the investigators to  measure midazolam 
and its metabolite is relatively complex, and involves 
mass spectral analysis. Same day turnaround for the 
results would probably require a dedicated laboratory 
and staff-an expensive proposition. Second, the dose 
of midazolam used (approximately 1 mg) will produce 
sedative effects in some patients and, therefore, the 
test may not be entirely without risk. 
It should also be noted that the information obtained 
from this “midazolam test” will probably be of limited 
value as a guide to oral dosing of cyclosporine (as op- 
posed to the intravenous dosing used in this study). In a 
recent s t ~ d y , ~  measurements of liver CYP3A4 activity 
using the intravenous erythromycin breath test sig- 
nificantly predicted variability in oral kinetics of 
cyclosporine in kidney transplant recipients, but the 
measurement accounted for less than 30% of this vari- 
ability. The inability of liver CW3A4 activity to accu- 
rately predict oral cyclosporine kinetics is undoubtedly 
multifactorial, and would be expected to include im- 
paired bile production in liver transplant recipients. 
However, an important factor is also likely to be first- 
pass metabolism of cyclosporine in the small intestine, 
where CYP3A4 is also quite a b ~ n d a n t . ~  Current data 
suggest that within an individual, the activity of 
CYP3A4 in intestine does not closely mirror the activity 
in liver (i.e., a given patient might have relatively high 
liver CYP3A4 activity while having relatively low in- 
testinal CYF’3A4 activity).6 This should be especially 
true in a liver transplant recipient in whom the liver 
and small bowel are of different genetic origin. Hence, 
tests that involve intravenous administration of 
CYP3A4 “probe” drugs such midazolam probably do not 
estimate the extent of intestinal metabolism of orally 
administered cyclosporine. A variety of investigators, 
including Dr Thummel’s group (Thummel K, Personal 
communication, March 1995), are now attempting to 
develop tests based on the oral administration of suit- 
able probe drugs that may be capable of measuring 
both liver and intestinal CYP3A4 a~ t iv i ty .~  
One final note, lidocaine conversion to the MEGX 
metabolite (the basis of the “MEGX test”) has been 
shown to be catalyzed by CYP3A4. Some data have 
recently been presented supporting the idea that the 
MEGX test result may in part reflect liver CYP3A4 
activity, and, therefore, might also be useful in dosing 
cyclosporine.* However, because lidocaine is very rap- 
idly cleared by the liver, variation in liver blood flow, 
and not just variation in liver CYP3A4 activity, should 
influence the MEGX test result. 
In summary, Thummel et a1 have provided the most 
clear-cut evidence to date supporting the idea that in- 
terpatient and intrapatient differences in hepatic 
CYP3A4 activity largely account for difficulty in arriv- 
ing at appropriate stable dosing of intravenous 
cyclosporine in liver transplant patients. The data they 
have obtained using midazolam highlight the feasibil- 
ity of developing convenient probe-based tests that 
could significantly improve the dosing of immunosup- 
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pressants to the transplant population, and could have 
wide implications in many other areas of clinical phar- 
macology. 
PAIJL B. WATKINS, MD 
University of Michigan 
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IMMUNOSUPPRESSION NOW WE HAVE CHOICES 
The U.S. Multicenter FK506 Liver Study Group. A 
comparison of tacrolimus (FK506) and cyclosporine for 
immunosuppression in liver transplantation. N Engl J 
Med 1994~331:1110-1115. 
ABSTRACT 
Background. Tacrolimus (FK 506), a macrolide com- 
pound isolated from a bacterium, is a potent immuno- 
suppressant with activity in solid-organ transplants. 
Most immunosuppressive regimens for liver trans- 
plantation are based on cyclosporine. 
Methods. We conducted an open-label, randomized, 
multicenter trial to compare the efficacy and safety of 
tacrolimus-based and cyclosporine-based immunosup- 
pressive regimens for patients receiving a first liver 
transplant. A total of 478 adults and 51 children (512  
years of age) were randomly assigned at the time of 
transplantation to receive tacrolimus (n = 263) or 
cyclosporine (n = 266) and were followed for one year. 
The primary end points were patient and graft survival 
at one year. The secondary end points were the inci- 
dence of acute rejection, corticosteroid-resistant rejec- 
tion, and refractory rejection (continued rejection after 
two courses of corticosteroids and an intervening course 
of muromonabCD3). 
Results. According to Kaplan-Meier analysis, actuarial 
patient-survival rates at day 360 were 88 percent for 
both the tacrolimus and cyclosporine groups (P  = 0.85; 
95 percent confidence interval for the difference, -5.4 
to 6.6 percent), and graft-survival rates were 82 percent 
and 79 percent, respectively (P  = 0.55; 95 percent confi- 
dence interval for the difference, -4.8 to 9.7 percent). 
Acute rejection occurred in 154 patients in the tacroli- 
mus group and 173 patients in the cyclosporine group 
(P  < 0.002), corticosteroid-resistant rejection occurred in 
43 and 82 patients, respectively (P  <0.001), and refrac- 
tory rejection occurred in 6 and 32 patients, respectively 
(P  <0.001). Tacrolimus was associated with a higher inci- 
dence of adverse events requiring withdrawal from the 
study, primarily nephrotoxicity and neurotoxicity; 37 
patients in the tacrolimus group and 13 in the 
cyclosporine group discontinued the study because of 
adverse events (P <0.001). 
Conclusions. After one year, immunosuppressive regi- 
mens based on tacrolimus and cyclosporine were compa- 
rable in terms of patient and graft survival. Tacrolimus 
was associated with significantly fewer episodes of 
acute, corticosteroid-resistant, or refractory rejection, 
but substantially more adverse events requiring discon- 
tinuation of the drug. (N Engl J Med 1994;331:1110-1115.) 
In the past decade, the surgical and medical aspects 
of orthotopic liver transplantation have been so refined 
as to result in excellent patient and graft survival for 
most indications. The lengthy and costly hospitaliza- 
tions of the past have been replaced by short postopera- 
tive hospital stays and more cost-effective patient man- 
agement. The question is no longer can the procedure 
be successfully performed, but rather, what is the most 
efficient and cost-beneficial method of performing the 
procedure. 
The main reasons for prolonged hospital stays and 
subsequent readmissions continue to be the complica- 
tions of too much or too little immunosuppression. 
These include rejection, infection, medication toxicity, 
and long-term complications, such as malignancy and 
renal failure. With a better understanding of the rejec- 
tion phenomena, immunosuppression can be better tai- 
lored to each individual patient, taking into account 
their specific immunosuppressive needs and liabilities. 
Tacrolimus is a welcome addition to the immunosup- 
pressive armamentarium, and this important article 
helps better define the role of this agent in the manage- 
ment of the transplant recipient. 
Although the 1-year patient and graft survival re- 
main the same between the two study groups, there is 
a clear-cut decrease in the number of rejection epi- 
sodes, the amount of steroid usage, and the number of 
refractory rejection episodes in the tacrolimus-treated 
group. Surprisingly, this did not impact on the patient 
survival, implying that the increased immunosuppres- 
sive effect is not at the cost of increased life-threatening 
infections. Or is tacrolimus toxicity merely counterbal- 
anced by the increased steroid use in the cyclosporine- 
treated group? Of interest would be a discussion of the 
infectious complications experienced by both groups as 
